MedicalResearch.com Interview with:
Eric A. Klein, MD
Chairman, Glickman Urological and Kidney Institute
MedicalResearch.com: Which of these results did you find most interesting or surprising?
Response: What’s most interesting is that the IsoPSA assay redefines how PSA is measured, which links it more closely to the underlying biology of cancer. Current assays measure only the concentration of PSA, which can be affected by conditions other than cancer – BPH most commonly, but also infection and inflammation – which limits its diagnostic accuracy for finding cancer. Its been known for several decades that PSA exists in multiple different forms in the bloodstream in patients with prostate cancer.
These novel molecules arise because cancer cells have deranged cellular metabolism that result in the generation of new species of PSA, making their measurement more tightly linked to the presence or absence of cancer and even the presence of high grade cancer (where cellular metabolism is even more disordered).
The IsoPSA assay is the first assay to measure all of these isoforms and thus has better diagnostic accuracy for cancer.